Lexicon Pharma (LXRX) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $1.48 --0%
Revenue Growth %: -79.9%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
KTB, CABO, FDUS, More
Revenue Growth %: -79.9%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.34), $0.04 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $11.11 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Amcor plc (AMCR) Misses Q1 EPS by 9c
- FatPipe, Inc. (FATN) Reports Q3 EPS of $0.09
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
